Lv4
566 积分 2024-05-15 加入
Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis
1个月前
已完结
Trends in Molecular Properties, Bioavailability, and Permeability across the Bayer Compound Collection
1个月前
已完结
Meeting report: DMPK optimisation strategies and quantitative translational PKPD frameworks to predict human PK and efficacious dose of targeted protein degraders
1个月前
已完结
Further Considerations Towards an Effective and Efficient Oncology Drug Discovery DMPK Strategy
1个月前
已完结
Global Analysis of Models for Predicting Human Absorption: QSAR, In Vitro , and Preclinical Models
1个月前
已完结
Beyond-Rule-of-Five Compounds Are Not Different: In Vitro–In Vivo Extrapolation of Female CD-1 Mouse Clearance Based on Merck Healthcare KGaA Compound Set
1个月前
已完结
Steering New Drug Discovery Campaigns: Permeability, Solubility, and Physicochemical Properties in the bRo5 Chemical Space
1个月前
已完结
Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders
1个月前
已完结
Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection
1个月前
已完结
Fundamental aspects of DMPK optimization of targeted protein degraders
1个月前
已完结
皖公网安备34019202002308
